Tonix Pharmaceuticals (NASDAQ:TNXP) has completed fed-fasting
and dose proportionality tests of TNX-102 SL in healthy volunteers,
data that, it says, should satisfy the pharmacokinetic requirements for
its U.S. marketing applications for posttraumatic stress disorder (PTSD)
and fibromyalgia.
Preliminary data showed no significant effect from
a fatty meal on the rate or extent of absorption of TNX-102 SL 5.6 mg
administered as 2 x 2.8 mg sublingual tablets.
Observed dose proportionality confirmed the prototype 2.4 mg formulation.
Shares up 42% premarket.
https://seekingalpha.com/news/3534291-tonix-pharma-up-42-premarket-on-advancement-of-tnxminus-102-sl
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.